Other News To Note
Thursday, April 28, 2011
Beactica AB, of Uppsala, Sweden, has entered into an agreement with Janssen Pharmaceutica NV, a subsidiary of New Brunswick, N.J.-based Johnson & Johnson, under which Beactica will use its Sprint drug discovery platform to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen. Financial details were not disclosed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.